Shots:

• The approval is based on P-III CheckMate -743 study assessing Opdivo + Yervoy vs SOC Pt. based CT in patients with previously untreated unresectable malignant pleural mesothelioma
• The combination regimen has demonstrated significant extension of OS vs CT. The safety profile of combination treatment was consistent with those previously reported in the studies for the combination treatment
• Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s immune system to help restore anti-tumor immune response. Yervoy is a recombinant- mAb and binds to the CTLA-4

  Ref: Ono Pharma | Image: BMS